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ates tumor necrosis factor-a (TNF-a)-induced ET-1 upregulation in human aortic endothelial cells
(HAECs) and sought to identify the signal pathways involved. TNF-a-induced reactive oxygen species
(ROS) activated Syk and phosphatidylinositol 3-kinase (PI3K), which was required for the activation
of AP-1 and subsequent ET-1 gene transcription. ROS mediated c-Jun NH2-terminal kinase (JNK) is
also required for AP-1 activation, but Syk and PI3K regulated AP-1 activation independently of
JNK. Through regulation of ET-1 production, Syk could be implicated in atherosclerosis.
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Endothelin-1 (ET-1) is implicated in the development of athero-
sclerosis [1]. Atherosclerosis begins with entrapment of athero-
genic lipoproteins to the proteoglycans in the subendothelium of
large arteries, which induces inﬂammatory responses [2]. During
this process, pro-inﬂammatory cytokines are released from inter-
actions among macrophages recruited from the circulation and
the cells comprising the vascular wall [3]. In vitro studies have
shown that pro-inﬂammatory cytokines stimulate endothelial cells
to secrete ET-1 [4]. ET-1 acts on the vascular smooth muscle cells
in a paracrine manner [5], and increases cell proliferation and
production of extracellular matrix [6,7], including proteoglycans
with longer glycosaminoglycan chains that have higher binding
afﬁnity to low density lipoprotein and, therefore, may cause fur-
ther entrapment of atherogenic lipoproteins [8] leading to progres-
sion of the atherosclerotic lesion. In the animal models, ET-1 mRNA
expression was elevated in the arteries of atherosclerotic lesion [9],
while antagonism of the ET-1 receptors reduced atheroscleroticchemical Societies. Published by E
ology, Department of Internal
Songpa P.O. Box 145, Seoullesion formation [10,11]. Thus, ET-1 is considered to be one of
the therapeutic targets for atherosclerosis [12].
In a previous study of cultured human aortic endothelial cells
(HAECs) [13], we demonstrated that tumor necrosis factor-a
(TNF-a) stimulates ET-1 production through reactive oxygen spe-
cies (ROS)-dependent c-Jun NH2-terminal kinase (JNK) and ROS-
independent p38 mitogen-activated protein kinase (MAPK) that
regulate both activator protein-1 (AP-1) and nuclear factor jB
(NF-jB). Scavenging ROS by antioxidant attenuated TNF-a-induced
ET-1 production.
Spleen tyrosine kinase (Syk), a non-receptor protein tyrosine
kinase, is a key mediator of Fc and B-cell receptor signaling in
inﬂammatory cells, such as B-cells, mast cells, macrophages and
neutrophils [14]. In T and B cells, Syk was activated by oxidative
stress as well as antigen receptor engagement [15,16]. Phosphat-
idylinositide 3-kinase (PI3K) was one of the signal transmitters
downstream to Syk that was activated by ROS [17]. Preclinical
study demonstrated that Syk inhibitor reduce inﬂammatory
response and ameliorate clinical symptoms of chronic inﬂamma-
tory diseases including allergic disease [18], rheumatoid arthritis
[19] and systemic lupus erythematosis [20].
Other studies have revealed that Syk is also expressed in
non-hematopoietic cells such as hepatocytes [21], synoviocytes
[22] and vascular endothelial cells [23]. In the synoviocytes [22]
and hematopoietic cells [24], Syk was shown to be activated bylsevier B.V. All rights reserved.
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which pro-inﬂammatory cytokines and ROS are involved, and Syk
may have a role in its pathogenesis. In a recent study [25] of
low-density lipoprotein receptor-deﬁcient mice, an oral spleen
tyrosine kinase inhibitor was shown to attenuate atherogenesis.
In the present study, we evaluated whether Syk is implicated in
the TNF-a-induced ET-1 upregulation in human aortic endothelial
cells (HAECs). In addition, we investigated how Syk regulates the
intracellular signal transduction pathways for TNF-a-induced
ET-1 gene expression.
2. Materials and methods
2.1. Materials
TNF-a was obtained from R&D Systems (Abingdon, UK). N-
acetylcysteine (NAC) and Bay 61-3606 were purchased from Sigma
(St. Louis, MO, USA). Syk inhibitor 574711 and SP600125 were
from EMD Chemicals Inc (Darmstadt, Germany). LY 294002 and
wortmannin were from Alexis biochemicals (San Diego, CA, USA).
Syk-siRNA, control-siRNA, and antibodies to human p65, actin,
PI3K, Syk, JNK, ERK, TGF-b1, and actin were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Antibodies to human phos-
pho-JNK (Thr183/Tyr185), phospho-p38 MAPK (Thr180/Tyr182),
phospho-ERK1/2 (Thr202/Tyr204) were from Cell Signaling Tech-
nology (Danvers, MA, USA). Antibody to human phospho-Syk
(pY525/526) was purchased from Epitomics (Burlingame, CA,
USA). Anti-phosphotyrosine (4G10) antibody was from Upstate
USA, Inc. (Chicago, IL, USA).
2.2. Cell culture
HAECs were obtained from Lonza Walkersville, Inc.
(Walkersville, MD, USA). The experiments were performed on cells
between passages 4 and 6. Before each experiment, the cells were
rested for 16 h in RPMI medium (Gibco BRL, Grand Island, NY, USA)
containing 2% fetal bovine serum. Prior to the addition of various
cell signal inhibitors and TNF-a, the medium was replaced with
serum-free RPMI medium.
2.3. Et-1 ELISA
Serum-starved HAECs were untreated or pretreated with Bay
61–3606 for 30 min and then incubated with TNF-a for 24 h. The
ET-1 released in cell culture supernatant was quantiﬁed by sand-
wich ELISA (QuantiGlo human ET-1, R&D Systems, Abingdon,
UK) according to the manufacture’s instruction. Each experiment
was performed in duplicates.
2.4. Real time reverse transcriptase-polymerase chain reaction (RT-
PCR) of ET-1 mRNA
Serum-starved HAECs were untreated or pretreated with NAC,
Syk inhibitors or PI3K inhibitors for 30 min and then incubated
with TNF-a for 12 h. Total RNA was extracted and reverse tran-
scribed to cDNA with a First Strand cDNA synthesis kit (Fermentas
Life Sciences, Burlington, ON, Canada) using random hexamer
primers. The mRNA levels of preproET-1 and b-actin were analyzed
by quantitative real-time PCR using the SYBR Green PCR Master
Mix Kit (Applied Biosystems, Foster City, CA, USA) and the ABI
Prism 7000 sequence detection system (Applied Biosystems). The
primers used were as follows; preproET-1, 50-TGCTCGTCCCTGAT
GGATAA-30 (forward) and 50-TCACGGTCTGTTGCCTTTGT-30 (re-
verse); b-actin, 50-CCCAAAGTTCACAATGTGGC-30 (forward) and
50-AAGTGGGGTGGCTTTTAGGA-30 (reverse). In each assay, weincluded a relative standard curve of four serial dilutions of cDNA.
Fold changes of preproET-1 and b-actin mRNAs in the experimental
samples relative to the control sample were calculated from the cy-
cle threshold numbers by interpolation on a standard curve for
each gene. Relative ET-1 gene expression was represented as the
fold change in preproET-1 mRNA corrected for that of b-actin
mRNA.
2.5. Preparation and transfection of decoy oligodeoxynucleotides
(ODNs)
The phosphorothioate double stranded ODNs against the NF-jB
and AP-1 binding site and the mismatched ODNs were prepared by
Bioneer Co. (Daejeon, Korea), based on the literature [26]. The
sequences of ODNs are as follows: NF-jB decoy ODN, 50-AGTTG
AGGGGACTTTCCCAGGC-30, mismatched NF-jB decoy ODN, 50-AG
TTGAGGCGACTTTCCCAGGC-30; AP-1 decoy ODN, 50-AGCTTGTGA
GTCAGAAGCT-30, mismatched AP-1 decoy ODN, 50-AGCTTGAAT
CTCAGAAGCT-30. The double stranded ODNs were prepared from
complementary single-stranded phosphorothiolate-bonded oligo-
nucleotides. Transfection of ODNs was performed to cells grown
in 100 mm dish to 80% conﬂuence. DNA was pre-complexed with
the opti-MEM reagents (GIBCO BRL, Grand Island, NY, USA) at room
temperature for 15 min, and then mixed and incubated with
diluted lipofectamine reagent (Life Technologies, Rockville, MD,
USA) for 15 min at room temperature. Thereafter, the reagent
complex was added to each dish containing fresh medium, and
incubated at 37 C at 5% CO2. After 6 h incubation, complete
medium with serum for normal growth was added. After 2 days
transfection period, the cells were subjected to the experiment
for real-time RT-PCR.
2.6. Electrophoretic mobility shift assay (EMSA)
Serum-starved HAECs were untreated or pretreated with NAC,
Syk inhibitors or PI3K inhibitors for 30 min and then incubated
with TNF-a for 30 min. After incubation periods, nuclear extract
was prepared. NF-jB and AP-1 consensus oligonucleotides (50-AG
TTGAGGGGACTTTCAGGA-30 and 50-CGCTTGATGAGTCAGCCGGAA-
30 respectively) (Promega, Madison, WI, USA) were end-labeled
with c-[32P]-ATP (50 lCi at 3000 Ci/mmol, New England Nuclear,
Boston, MA, USA) with T4 polynucleotide kinase. Nuclear protein
(10 lg) was allowed to react for 15 min with 32P-labeled NF-jB
or AP-1 oligonucleotides (1.75 pmol) in 25 lL of binding buffer.
Nucleoprotein–oligonucleotide complexes were resolved by elec-
trophoresis on a 6% non-denaturing polyacrylamide gel. Thereafter,
the gel was dried and DNA–protein complexes were localized by
autoradiography for 6–12 h. For the competitive assay, 100 times
excess unlabeled NF-jB or AP-1 oligonucleotides were added in
the reaction mixture before adding the 32P-labeled NF-jB or AP-1
oligonucleotides.
2.7. Western blot analysis
Treated cells were washed with PBS, and incubated with 100 ll
of lysis buffer containing 50 mM KCl, 25 mM HEPES (pH 7.8), 0.5%
Igepal CA-630, 1 mM PMSF, 2 lM leupeptin, 1 lM aprotinin and
100 lM DTT on ice for 5 min. For the experiment using nuclear
extract, cytosolic fractions were separated using pipette after
centrifugation and the remaining nuclear fractions were lysated
again with lysis buffer. After repeated freezing and thawing with
liquid nitrogen and water bath set to 37 C, the nuclear lysates
were incubated at 4 C for 20 min with a rocking platform. Finally,
nuclear protein was obtained after centrifugation. In other
experiments, whole cell lysates were used. Equal amounts of
Fig. 1. TNF-a-induced ET-1 production. (A) HAECs were seeded on each well of 24
well plates and cultured for 24 h, and then were serum-starved for 16 h. The cells
were treated TNF-a (1 ng/ml) for 15 min, 30 min, 1 h, 6 h, 12 h, and 24 h. ET-1 in the
supernatant was measured by ELISA. (B) In another experiment, HAECs were
treated with different doses of TNF-a (0, 0.1, 1, 2 and 10 ng/ml) for 24 h and ET-1 in
the supernatant was measured. (⁄P < 0.05 compared with control; n = 4).
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electrophoresis, and transferred to an Immobilon-P transfer mem-
brane (Millipore, Bedford, MA, USA). The membrane was probed
with the antibody directed against human p65, actin, phospho-
Syk (Try525/526), Syk, phospho-JNK (Thr183/Tyr185), JNK, phos-
pho-p38 MAPK (Thr180/Tyr182), p38 MAPK, phospho-ERK1/2
(Thr202/Tyr204), or ERK. Bands were visualized using horseradish
peroxidase conjugated anti-rabbit IgG (Santa Cruz Biotechnology).
2.8. Measurement of ROS
The production of intracellular ROS was evaluated with the
probe 5-(and-6)-chloromethyl-20-70-dichlorodihydroﬂuorescein
diacetate (CM–H2DCF–DA; Molecular Probes, Eugene, OR, USA).
This reagent enters into cells, and reacts with ROS to generate
the ﬂuorescent product 20-70-dichloroﬂuorescein. Serum-starved
HAECs were untreated or pretreated with NAC, Syk inhibitors or
PI3K inhibitors for 30 min and then incubated with TNF-a for
30 min. Thereafter, the cells were incubated with 5 lmol/L of
H2DCF-DA for 10 min at 37 C. After removal of the media and
wash of the cells, the expression of intracellular ROS was visualized
with a LEICA DM-IRE2 inverted microscope (Leica microsystem
GmbH, Wetzlar, Germany) equipped with Leica TCS-SP2 confocal
system (excitation 488 nm, emission 520 nm). The ﬂuorescent
intensities were measured using image-analysis software (Image-
Pro Plus; MediaCybernetics, Bethesda, MD, USA).
2.9. Immunoprecipitation
Equal amounts (100 lg) of whole cell lysates were immunopre-
cipitated by addition of antibody to PI3K (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA). Immune complexes were recovered by
addition of protein A-agarose (Roche Applied Science, Indianapolis,
IN, USA) and analyzed by Western blotting with anti-phosphotyro-
sine (4G10) antibody.
2.10. Transfection of small interfering RNA (siRNA)
Transfection of siRNA directed against Syk (Syk-siRNA) or a
non-speciﬁc, scrambled, control siRNA (control-siRNA) was also
performed using lipofectamine reagent. After transfection of
100 pmol siRNA, the cells were maintained with complete medium
for 3 days and then serum-starved for 16 h and subjected to the
experiments.
2.11. Statistical analysis
Data are presented as mean ± S.E.(standard error), with n repre-
senting the number of different experiments. A Student0s t-test was
used to compare two values, and an analysis of variance (ANOVA)
followed by Dunnett multiple-comparisons test was used to com-
pare mean values among three or more groups. P < 0.05 was con-
sidered statistically signiﬁcant.
3. Results
3.1. TNF-a-induced ET-1 production
HAECs were treated TNF-a (1 ng/ml) for 15 min, 30 min, 1 h,
6 h, 12 h, and 24 h. ET-1 production was measured in the superna-
tant. TNF-a increased ET-1 production in a time-dependent
manner (Fig. 1A). In another experiment, HAECs were treated with
different doses of TNF-a (0, 0.1, 1, 2 and 10 ng/ml) for 24 h and
ET-1 production was measured. TNF-a increased ET-1 production
in a dose-dependent manner (Fig. 1B).3.2. Syk mediates TNF-a-induced ET-1 production
ET-1 protein level was measured in the supernatant after the
HAECs were pretreated with/without Bay 61-3606 (1 or 10 lM)
for 30 min and then incubated with TNF-a (1 ng/ml) for 24 h.
TNF-a signiﬁcantly increased ET-1 production as compared with
control (each n = 6, P < 0.05). In contrast, TNF-a-induced ET-1 pro-
duction was effectively attenuated by pretreatment with Bay 61-
3606 in a dose-dependent manner (Fig. 2A).
Stimulation of HAECs with TNF-a (1 ng/ml) for 12 h resulted in
a signiﬁcant increase in preproET-1 mRNA. Pre-incubation with
Bay 61-3606 (1 lM) or Syk inhibitor 574711 (1 lM) attenuated
TNF-a-induced elevation in preproET-1 mRNA (Fig. 1B). NAC
(5 mM) also inhibited TNF-a-induced preproET-1 at mRNA levels
(Fig. 2B). To see the effect of speciﬁc depletion of Syk protein on
TNF-a-induced preproET-1 mRNA, we transfected Syk-siRNA or
control-siRNA into the cells before treatment with TNF-a. As
shown in Fig. 2C, Syk-siRNA effectively inhibited TNF-a-induced
preproET-1 mRNA expression.
3.3. PI3K mediates TNF-a-induced ET-1 production
We investigated whether PI3K is also involved in TNF-
a-induced ET-1 production. As shown in Fig. 3, both LY 294002
(25 lM) and wortmannin (0.1 lM) signiﬁcantly inhibited TNF-
a-induced preproET-1 mRNA expression.
3.4. Syk and PI3K regulate TNF-a-induced activation of AP-1
To assess whether activation of AP-1 or NF-jB is implicated in
TNF-a-induced ET-1 gene transcription, the cells were transfected
Fig. 2. Syk mediates TNF-a-induced ET-1 production. (A) Effect of Syk inhibitor on TNF-a-induced ET-1 production. HAECs were seeded on each well of 24 well plates and
cultured for 24 h, and then were serum-starved for 16 h. The cells were pretreated with/without Bay 61-3606 (1 and 10 lM) for 30 min and then incubated with TNF-a (1 ng/
ml) for 24 h. The supernatants were collected and ET-1 was measured by ELISA. (⁄P < 0.05 compared with control; ⁄⁄P < 0.05 as compared with cells stimulated with TNF-a;
n = 6). (B) Effects of NAC or Syk inhibitors on TNF-a-induced preproET-1 mRNA expression. Serum-starved HAECs were pretreated with/without NAC (5 mM), Bay 61-3606
(1 lM), Syk inhibitor 574711 (1 lM) or vehicle (DMSO) for 30 min and then incubated with TNF-a (1 ng/ml) for 12 h. PreproET-1 mRNA levels were measured by real-time
RT-PCR and expressed as fold induction after normalization to b-actin. (⁄P < 0.05 compared with control; ⁄⁄P < 0.05 compared with TNF-a; n = 8). (C) Syk-siRNA attenuates
TNF-a-induced preproET-1 mRNA expression. Cells were transfected with Syk-siRNA or control siRNA and then treated with TNF-a (1 ng/ml) for 12 h. PreproET-1 mRNA
levels were measured by real-time RT-PCR and expressed as fold induction after normalization to b-actin. (⁄P < 0.05 compared with control; n = 8).
Fig. 3. PI3K mediates TNF-a-induced ET-1 production. Serum-starved HAECs were
pretreated with/without LY 294002 (25 lM) or wortmannin (0.1 lM) for 30 min
and then incubated with TNF-a (1 ng/ml) for 12 h. PreproET-1 mRNA levels were
measured by real-time RT-PCR and expressed as fold induction after normalization
to b-actin. (⁄P < 0.05 compared with control; ⁄⁄P < 0.05 compared with TNF-a;
n = 8).
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TNF-a. Either AP-1 or NF-jB decoy ODNs signiﬁcantly inhibited
TNF-a-induced preproET-1 mRNA expression as compared withmismatched decoy ODNs (Fig. 4A). In the EMSA, TNF-a increased
DNA binding activities of AP-1 and NF-jB, whereas NAC (5 mM)
downregulated TNF-a-induced DNA binding activities of both AP-
1 and NF-jB (Fig. 4B and C).
To determine whether Syk or PI3K are linked to DNA-binding
activity of AP-1 or NF-jB, the cells were pretreated with or without
Syk inhibitors and PI3K inhibitors for 30 min and the incubated
with TNF-a. Both Syk inhibitors (Bay 61–3603 and Syk inhibitor
574711) and PI3K inhibitors (LY 294002 and wortmannin) down-
regulated TNF-a-induced DNA binding activity of AP-1 (Fig. 4B),
but not NF-jB (Fig. 4C).
We next evaluated the effect of NAC, Syk inhibitors and PI3K
inhibitors on the dynamics of p65 protein. The cells were pre-
treated with/without NAC (5 mM), Bay 61–3606 (1 lM), Syk inhib-
itor 574711 (1 lM), LY 294002 (25 lM) or wortmannin (0.1 lM)
for 30 min and then incubated with TNF-a (1 ng/ml) for 30 min,
and nuclear extracts from the cells were evaluated. All the inhibi-
tors including NAC did not alter TNF-a-induced nuclear transloca-
tion of p65 (Fig. 4D).
3.5. ROS is upstream to Syk and PI3K
TNF-a increased intracellular ROS generation. NAC, an antioxi-
dant, scavenged TNF-a-induced ROS (Fig. 5). In contrast, Syk inhib-
itors (BAY 61-3606 and Syk inhibitor 574711) as well as PI3K
inhibitors (LY 294002 and Wortmannin) had no effect on TNF-
a-induced ROS generation.
Fig. 4. Syk and PI3K regulate TNF-a-induced activation of AP-1, but not NF-jB. (A) Involvement of AP-1 and NF-jB in TNF-a-induced preproET-1 mRNA expression. Cultured
HAECs were transfected with AP-1 or NF-jB decoy oligodeoxynucleotides, or mismatched oligodeoxynucleotides. After serum-starvation, the cells were incubated with TNF-
a (1 ng/ml) for 12 h. PreproET-1 mRNA levels were measured by real-time RT-PCR and expressed as fold induction after normalization to b-actin. (⁄P < 0.05 compared with
control; ⁄⁄P < 0.05 compared with TNF-a; n = 8). (B, C) Effects of NAC, Syk inhibitors or PI3K inhibitors on the TNF-a-induced DNA binding activities of AP-1 (B) and NF-jB (C).
Serum-starved HAECs were treated with/without NAC (5 mM), Bay 61-3606 (1 lM), Syk inhibitor 574711 (1 lM), LY 294002 (25 lM) or wortmannin (0.1 lM) for 30 min and
then incubated with TNF-a (1 ng/ml) for 30 min. The nuclear extracts were assayed for the ability to bind 32P-labeled AP-1 or NF-jB oligonucleotides by EMSA. To determine
the speciﬁcity of the band, 100 times excess unlabeled AP-1 or NF-jB oligonucleotides was added in the reaction mixture before adding the 32P-labeled AP-1 or NF-jB
oligonucleotides. The results shown are representative of three independent experiments. (D) Effects of NAC, Syk inhibitors or PI3K inhibitors on the TNF-a-induced nuclear
translocation of p65. Serum-starved HAECs were treated with/without NAC (5 mM), Bay 61-3606 (1 lM), Syk inhibitor 574711 (1 lM), LY 294002 (25 lM) or wortmannin
(0.1 lM) for 30 min and then incubated with TNF-a for 30 min. The nuclear lysates were analyzed by western blotting using anti-p65 antibody. The result shown is
representative of three independent experiments.
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To investigate the relation between Syk and PI3K, HAECs were
preincubated with Syk inhibitors or transfected with Syk-siRNA,
and then TNF-a-induced tyrosine phosphorylation of PI3K was
assessed. After treatment with TNF-a (1 ng/ml) for 15 min, whole
cell extracts were obtained and immunoprecipitated with
anti-PI3K antibody, and then subjected to Western blot using
anti-phosphotyrosine antibody. As shown in Fig. 6A, Bay 61-3606
(1 lM) or Syk inhibitor 573711 (1 lM) attenuated TNF-a-induced
tyrosine phosphorylation of PI3K. In addition, Syk-siRNA also
inhibited TNF-a-induced tyrosine phosphorylation of PI3K
(Fig. 6B). Activation of Syk requires phosphorylation of tyrosine
in the activation loop of the Syk kinase domain [27]. As shown in
Fig. 6C, TNF-a increased tyrosine phosphorylation of Syk, while it
was inhibited by PI3K inhibitors and NAC. PI3K-siRNA also
inhibited TNF-a-induced tyrosine phosphorylation of Syk (Fig. 6D).
3.7. Syk and JNK independently regulate AP-1
Like Syk, JNK was also downstream to ROS and required for
AP-1 activation in our previous study [13]. Thus, we explored therelation between Syk and JNK in the signal pathway for TNF-a-in-
duced ET-1 production. Both Syk inhibitors and PI3K inhibitors had
no effect on TNF-a-induced phosphorylation of JNK, while NAC
inhibited it (Fig. 7A). JNK inhibitor (SP600125, 10 lM) had no effect
on TNF-a-induced tyrosine phosphorylation of Syk (Fig. 7B). To
further investigate the relation between Syk and MAPKs in TNF-
a-induced signal transduction pathway, we examined the activa-
tion of MAPKs after TNF-a stimulation in the cells transfected
Syk-siRNA or control-siRNA. As shown in Fig. 7C, Syk-siRNA
suppressed the Syk protein expression, but did not have an effect
on TNF-a-induced JNK, p38 MAPK, or ERK activation.
4. Discussion
ET-1 released from aortic endothelial cells promotes the pro-
gression of atherosclerosis [1]. To investigate a possibility of the
implication of Syk in the development of atherosclerosis, we
explored whether Syk mediates TNF-a-induced ET-1 production
in HAECs. TNF-a activated Syk, whereas both Syk inhibitors, Bay
61-3606 and Syk inhibitor 574711, attenuated TNF-a-induced
ET-1 production. In addition, speciﬁc inhibition of Syk by transfec-
tion of Syk-siRNA also downregulated TNF-a-induced ET-1 gene
Fig. 5. ROS is upstream to Syk and PI3K. Serum-starved HAECs were treated with/without NAC (5 mM), Syk inhibitors (Bay 61–3606, 1 lM: Syk inhibitor 574711, 1 lM) or
PI3K inhibitors (LY 294002, 25 lM: wortmannin, 0.1 lM) for 30 min and then incubated with TNF-a (1 ng/ml) for 30 min. Thereafter, the cells were loaded with 5 lM CM-
H2DCF-DA and incubated for 10 min at 37 C. After removal of the media, the cells were washed and the expression of intracellular ROS was visualized with confocal
microscopy. (200). The bar graph shows relative DCF ﬂuorescent intensities (⁄P < 0.05 compared with control; ⁄⁄P < 0.05 compared with TNF-a; n = 3).
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implicated in TNF-a-induced ET-1 production.
In a previous study of HAECs [13], we demonstrated that TNF-a
induces ET-1 gene expression through AP-1 and NF-jB. TNF-a
activates all the 3 major MAPKs, including JNK, p38 MAPK and
extracellular signal-regulated kinase (ERK). Of the MAPKs, JNK
and p38 MAPK, but not ERK, regulate the activations of both AP-
1 and NF-jB that were required for TNF-a-induced ET-1 gene
expression. The activation of JNK was regulated by upstream
ROS. Though p38 MAPK has been shown to be redox-sensitive in
several types of cells [28,29], it was activated independently of
ROS in HAECs. This was consistent with another our previous study
[30], in which darbepoetin alfa that has an antioxidant effect sup-
pressed TNF-a induced JNK activation, but not p38 MAPK activa-
tion. The existence of ROS-independent p38 MAPK activation
pathway in the downstream of TNF-a signaling was also suggested
in other studies [31–33]. On the basis of these ﬁndings, in the pres-
ent study, we further investigated how Syk is involved in the signal
pathway for TNF-a-induced ET-1 gene expression. Syk activation
was inhibited by NAC while the generation of ROS was not inhib-
ited by Syk inhibitors. Thus, our data showed that Syk is activated
downstream to ROS. PI3K also mediated TNF-a-induced ET-1 gene
expression. In the present study, Syk inhibitors or Syk-siRNA sup-
pressed TNF-a-induced tyrosine phosphorylation of PI3K, while
PI3K inhibitors attenuated Syk activation, suggesting an interac-
tion between Syk and PI3K.As above, both Syk and JNK were downstream to ROS. With
regard to the relation between Syk and JNK, there was a study that
Syk regulates TNF-a-induced JNK activation in synoviocytes
because Syk inhibitors attenuated TNF-a-induced JNK activation
via inhibition of MKK4, the upstream kinase of JNK [22]. However,
the signal pathway in HAECs was different from that in
synoviocytes. Though both Syk and PI3K also were required for
AP-1 activation, either Syk or PI3K was not linked to JNK activation
as shown by the ﬁndings that Syk-siRNA, inhibitors of Syk or PI3K
had no effect on TNF-a-induced JNK activation, and JNK inhibitor
also had no effect on TNF-a-induced Syk activation. Thus, Syk
and its downstream signal pathway seem to regulate AP-1 inde-
pendently of JNK. Though the present study did not elucidate
how Syk and PI3K regulate AP-1 independently of JNK, there was
a study that supports this possibility. In pancreatic cancer cells
[34], Akt, which is downstream to PI3K, was shown to directly reg-
ulate the transcriptional activity of c-Jun independently of the
phosphorylation sites targeted by JNK (Ser63/Ser73).
There was also a study suggesting the regulatory role of Syk in
the activation of NF-jB. In hematopoietic cell lines [24], Syk activa-
tion by TNF-a resulted in MAPK phosphorylation and NF-jB trans-
location. On contrast, in HAECs, both Syk inhibitors and PI3K
inhibitors could not inhibit either TNF-a-induced p65 nuclear
translocation or DNA-binding activity of NF-jB. NAC, an antioxi-
dant, also had no effect on TNF-a-induced p65 nuclear transloca-
tion, but it inhibited DNA-binding activity of NF-jB. As shown in
Fig. 6. Syk interacts with PI3K. (A) Effects of NAC or Syk inhibitors on TNF-a-induced PI3K tyrosine phosphorylation. Serum-starved HAECs were treated with/without NAC
(5 mM), Bay 61–3606 (1 lM) or Syk inhibitor 574711 (1 lM) for 30 min and then incubated with TNF-a (1 ng/ml) for 15 min. The whole cell lysates were
immunoprecipitated with anti-PI3K antibody and then subjected to immunoblot analysis using anti-phosphotyrosine antibody. The membranes were stripped and
reprobed with anti-PI3K antibody, respectively. The result shown is representative of three independent experiments. (⁄P < 0.05 compared with control; ⁄⁄P < 0.05 as
compared with cells stimulated with TNF-a). (B) Effects of Syk-siRNA on TNF-a-induced PI3K tyrosine phosphorylation. Cells were transfected with control siRNA or Syk-
siRNA and then treated with TNF-a (1 ng/ml) for 15 min. The whole cell lysates were immunoprecipitated with anti-PI3K antibody and then subjected to immunoblot
analysis using anti-phosphotyrosine antibody. The membranes were stripped and reprobed with anti-PI3K antibody, respectively. The results shown are representative of
three independent experiments. (⁄P < 0.05 compared with control). (C) Effects of NAC or PI3K inhibitors on TNF-a-induced Syk activation. Serum-starved HAECs were treated
with/without NAC (5 mM), LY 294002 (25 lM) or wortmannin (0.1 lM) for 30 min and then incubated with TNF-a (1 ng/ml) for 10 min. Whole-cell lysates were
immunoblotted with an anti-phospho-Syk antibody. Thereafter, the membranes were stripped and reprobed with an anti-Syk antibody. A representative blot from one of four
independent experiments is shown. The bar graph shows the relative densities of phospho-Syk/Syk bands (⁄P < 0.05 compared with control; ⁄⁄P < 0.05 as compared with cells
stimulated with TNF-a). (D) Effects of PI3K-siRNA on TNF-a-induced Syk activation. Cells were transfected with control siRNA or PI3K-siRNA and then treated with TNF-a
(1 ng/ml) for 15 min. Phosphorylation of Syk was measured as in C. The results shown are representative of ﬁve independent experiments. The bar graph shows the relative
densities of phospho-Syk/Syk bands (⁄P < 0.05 compared with control).
824 Y.J. Kim et al. / FEBS Letters 586 (2012) 818–826our previous study [13], NAC inhibits ROS-dependent activation of
JNK as well as ROS-dependent Syk. Inhibition of JNK by NAC results
in inhibition of Ser276 phosphorylation of p65 that is required for
DNA-binding of NF-jB. This also supports that Syk and JNK are not
in a vertical line in the pathway for TNF-a-induced ET-1 gene
expression in HAECs.
Taken together the ﬁndings of the present and our previous
studies, TNF-a-induced intracellular signal pathways leading to
ET-1 gene expression in HAECs may be summarized as shown in
Fig. 8. TNF-a-induced ET-1 gene expression occurs through JNK
and p38 MAPK, both of which regulate AP-1 and NF-jB. Both Syk
and JNK are dependent on ROS while p38 MAPK is not. With regard
to NF-jB activation, JNK and p38 MAPK has no effect on either
IjBa degradation or nuclear translocation of p65, but increases
p65 phosphorylation on serine 276 and DNA binding activity of
NF-jB. Syk interacts with PI3K and both regulates AP-1 activation
independently of JNK.Recently, Syk has emerged as a new promising therapeutic
target for chronic inﬂammatory diseases including allergic rhini-
tis [18], rheumatoid arthritis [19] and lupus nephritis [20]. Phase
2 clinical trials of fostamatinib, an oral form of Syk inhibitor,
demonstrated considerable beneﬁcial effects on rheumatoid
arthritis [19] and immune thrombocytopenic purpura [35]. Syk
could also be a potential therapeutic target for atherosclerosis.
In a recent study [25], atherosclerotic lesions of human carotid
arterial tissue as well as mice aortic root were shown to contain
more phosphorylated Syk than healthy control tissues. In
addition, the Syk inhibitor, fostamatinib, dose-dependently atten-
uated atherosclerotic lesion in low-density lipoprotein receptor-
deﬁcient mice consuming a high-cholesterol diet. In another
study [36], Syk was shown to mediate minimally oxidized low-
density lipoprotein-induced stimulation of macropinocytosis
resulting in lipid accumulation in macrophages, which is an
early and critical step in the initiation and progression of
Fig. 7. Syk and JNK independently regulate AP-1. (A) Effects of NAC, Syk inhibitors or PI3K inhibitors on TNF-a-induced JNK phosphorylation. Serum-starved HAECs were
treated with/without NAC (5 mM), Bay 61–3606 (1 lM) or Syk inhibitor 574711 (1 lM), LY 294002 (25 lM) or wortmannin (0.1 lM) for 30 min and then incubated with TNF-
a for 15 min. The whole cell lysates were analyzed by western blotting with anti-phospho-JNK antibody. The membranes were stripped and reprobed with anti-JNK antibody,
respectively. The result shown is representative of three independent experiments. (B) Effect of JNK inhibitor on TNF-a-induced tyrosine-phosphorylation of Syk. Serum-
starved HAECs were treated with/without SP6001125 (10 lM) for 30 min and then incubated with TNF-a (1 ng/ml) for 10 min. Whole-cell lysates were immunoblotted with
an anti-phospho-Syk antibody. Thereafter, the membranes were stripped and reprobed with an anti-Syk antibody. A representative blot of three independent experiments is
shown. The bar graph shows the relative densities of phospho-Syk/Syk bands (⁄P < 0.05 compared with control). (C) Effects of Syk-siRNA on TNF-a-induced MAPK activations.
Cells were transfected with control siRNA or Syk-siRNA and then treated with TNF-a (1 ng/ml) for 20 min. The whole cell lysates were immunoblotted with an anti-phospho-
JNK, anti-phospho-p38 MAPK, anti-phospho-ERK, or anti-Syk antibodies. Thereafter, the membranes were stripped and reprobed with anti-JNK, anti-p38 MAPK, anti-ERK, or
anti-actin antibodies. The results shown are representative of four independent experiments. The bar graphs show the relative densities of phospho-JNK/JNK, phospho-p38
MAPK/p38 MAPK, phospho-ERK/ERK, Syk/actin bands (⁄P < 0.05 compared with control).
Y.J. Kim et al. / FEBS Letters 586 (2012) 818–826 825atherosclerosis. Because ET-1 is pro-atherogenic [7], the critical
role of Syk in TNF-a-induced ET-1 gene expression shown in
the present study also supports the possibility that Syk could
be implicated in atherosclerosis.
In summary, TNF-a-induced ROS activated Syk and PI3K that
were required for the activation of AP-1 and subsequent ET-1 gene
transcription. Through the regulation of ET-1 production, Syk could
be implicated in atherosclerosis.5 Sources of funding
This study was supported by a grant (2203-070) from the Asan
Institute for Life Sciences (Seoul, Korea).
Acknowledgment
None.
Fig. 8. A schematic diagram demonstrating TNF-a-induced intracellular signal
pathways leading to ET-1 gene expression in HAECs and the role of Syk, based on
the ﬁndings of the present study and our previous studies. TNF-a-induced ET-1
gene expression occurs through JNK and p38 MAPK, both of which regulate AP-1
and NF-jB. Both Syk and JNK are dependent on ROS while p38 MAPK is not. With
regard to NF-jB activation, JNK and p38 MAPK has no effect on either IjBa
degradation or nuclear translocation of p65, but increases p65 phosphorylation on
serine 276 and DNA binding activity of NF-jB. Syk interact PI3K and both regulates
AP-1 activation independently of JNK.
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